A Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Tolerability, and Efficacy of PBT2 in Patients With Early to Mid-stage Huntington Disease.

Trial Profile

A Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Tolerability, and Efficacy of PBT2 in Patients With Early to Mid-stage Huntington Disease.

Completed
Phase of Trial: Phase II

Latest Information Update: 18 Oct 2016

At a glance

  • Drugs PBT 2 (Primary)
  • Indications Huntington's disease
  • Focus Adverse reactions
  • Acronyms Reach2HD
  • Sponsors Prana Biotechnology
  • Most Recent Events

    • 18 Oct 2016 According to Prana Biotehnology media release, the cognitive results of this study were presented at the American Neurological Association (ANA) Annual Meeting.
    • 27 Apr 2015 According to Prana Biotehnology media release, US Food and Drug Administration granted PBT2 orphan drug status for the treatment of Huntington disease and European Medicines Agencys Committee for Orphan Medicinal Products (COMP) has adopted a positive opinion recommending designation of PBT2 for the treatment of Huntington disease as an orphan medicinal product to the European Commission (EC).
    • 10 Dec 2013 Results are expected to be reported in the first quarter of 2014, according to a Prana Biotherapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top